Lantheus Holdings, Inc. $LNTH Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 206,472 shares of the medical equipment provider’s stock after buying an additional 10,722 shares during the period. Principal Financial Group Inc. owned 0.30% of Lantheus worth $10,590,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LNTH. Arizona State Retirement System boosted its holdings in Lantheus by 2.4% in the third quarter. Arizona State Retirement System now owns 20,450 shares of the medical equipment provider’s stock valued at $1,049,000 after acquiring an additional 487 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in Lantheus during the third quarter worth about $59,000. Sector Gamma AS raised its holdings in shares of Lantheus by 28.0% in the 3rd quarter. Sector Gamma AS now owns 64,403 shares of the medical equipment provider’s stock worth $3,303,000 after purchasing an additional 14,102 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Lantheus in the 3rd quarter valued at about $3,866,000. Finally, UNIVEST FINANCIAL Corp lifted its stake in shares of Lantheus by 46.0% in the 3rd quarter. UNIVEST FINANCIAL Corp now owns 31,024 shares of the medical equipment provider’s stock valued at $1,591,000 after purchasing an additional 9,781 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on LNTH. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Mizuho lifted their target price on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, Truist Financial upped their price target on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Stock Performance

Shares of LNTH stock opened at $67.28 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The company’s fifty day moving average price is $66.04 and its two-hundred day moving average price is $59.52. The firm has a market capitalization of $4.46 billion, a P/E ratio of 28.27 and a beta of -0.08. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.